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Abstract
In the late 1960s, the combination of trimethoprim and sulphamethoxazole (co-trimoxazole) was introduced into clinical practice and
used to treat many infectious diseases, such as urinary tract infections, respiratory infections, sexually transmitted diseases, Gram-negative
sepsis, enteric infections and typhoid fever. Subsequently, co-trimoxazole was reported to be effective against numerous bacterial, fungal
and protozoal pathogens, including Nocardia, Listeria monocytogenes, Brucella, Stenotrophomonas maltophilia, Burkholderia, Coxiella burnetii,
Tropheryma whipplei, atypical mycobacteria, and Pneumocystis jirovecii. Among protozoal infections, in addition to toxoplasmosis, co-trimox-
azole has been used to treat susceptible Plasmodium falciparum, Cyclospora and Isospora infections. Several retrospective and prospective
studies have demonstrated good clinical outcome with co-trimoxazole in treating invasive methicillin-resistant Staphylococcus aureus
infections. We summarize herein the accumulated evidence in the literature on the new, ‘unconventional’ clinical use of co-trimoxazole
during the last three decades. In the era of widespread antibiotic resistance and shortage of new antibiotic options, large-scale,
well-designed studies are needed to explore the tremendous potential concealed in this well-established drug.
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Introduction
In the era of rapidly escalating antibiotic resistance, along
with stagnation of novel antimicrobial production, better
compliance with infection control measures and rational use
of new antimicrobial agents has become more crucial than
ever. In addition, every older antimicrobial agent in our arse-
nal should be maximally ‘squeezed’.
Trimethoprim–sulphamethoxazole (co-trimoxazole) is a
well-established compound that is extensively used for various
indications in countries with limited resources, offering an
additional option in the battle against many pathogens, owing
to its low cost, acceptable toxicity proﬁle, availability by both
oral and intravenous routes, and bactericidal activity. In the
1930s, a promising new compound was found to possess anti-
microbial qualities, especially in animal models. This com-
pound, Prontosil, was one of the ﬁrst sulphonamide dyes to
demonstrate antistreptococcal activity together with a good
safety proﬁle [1]. Several modiﬁed sulphonamide preparations
were produced in later years, improving the safety and speciﬁc
anti-infectious activity in different sites, such as the central ner-
vous system (CNS), respiratory tract and urinary tract [2].
Trimethoprim was ﬁrst synthesized during the 1950s, and
immediately demonstrated antibacterial activity in vitro [3].
During the next decade, it was used in different clinical set-
tings, such as chronic bronchitis, staphylococcal pneumonia,
Gram-negative bacteraemia and urinary tract infections [4].
Because of the closely relatedmechanisms of action, the com-
bination of trimethoprim and sulphamethoxazole (Fig. 1) was
investigated immediately, andwas found to be synergistic [4].
During the ﬁrst 2 years of clinical experience, co-trimox-
azole was reported to be effective in different clinical condi-
tions, such as urinary tract infections, respiratory tract
infections, sexually transmitted diseases, Gram-negative sep-
sis and typhoid fever [5]. However, widespread use of this
drug has led to increasing resistance rates among enteric and
respiratory pathogens, peaking during the 1990s [6]. Gradu-
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ally, its use in these ‘conventional’ settings diminished, while
other clinical uses were being explored.
During the last three decades, co-trimoxazole re-emerged
as an effective treatment for numerous pathogens, including
bacteria, fungi and parasites. Its effectiveness has been well
documented in some studies, whereas in others the data are
sparse and of low quality.
In this review, we present updated data regarding the
‘unconventional’ use of this drug, other than for nocardiosis,
toxoplasmosis and Pneumocystis jiroveci pneumonia. Table 1
summarizes the reported literature on the clinical use of co-
trimoxazole during the past three decades.
Bacterial Pathogens
Actinomyces
Evidence of in vitro susceptibility of Actinomyces to co-trimox-
azole exists in the literature [7]. However, very few clinical
data are available. Several case series describe successful
treatment of actinomycetoma and skin infections with co-
trimoxazole [8,9], usually in combination with other drugs,
such as penicillin, ampicillin, gentamicin and doxycycline.
Aeromonas hydrophila
Aeromonas spp. have good in vitro susceptibility to co-trimox-
azole [10], although there is a wide range of susceptibility,
depending on the speciﬁc species and geographical location.
There are sparse clinical data showing successful treatment
of mainly gastroenteritis and skin and soft tissue infections
with co-trimoxazole used as monotherapy [11,12], but they
are derived from case series and case reports only.
Achromobacter
This emerging nosocomial pathogen shows over 75% suscep-
tibility to co-trimoxazole in vitro. Clinical data consist of small
case series [13,14] and case reports demonstrating good
clinical outcome in most patients, especially in bacteraemia
and urinary tract infection.
Stenotrophomonas maltophilia
This pathogen is a growing threat to hospitalized patients,
especially if they are immunosuppressed. Susceptibility to co-
trimoxazole has been known and reported for a long time.
Clinical information has been derived from numerous case
reports, including cases of endocarditis and meningitis. Ret-
rospective studies have demonstrated clinical success in
cases of bacteraemia or sepsis [15,16]. A systematic review
of skin infections with this pathogen in patients with haema-
tological malignancy demonstrated good cure rates [17].
However, resistance is already developing, and may limit the
use of co-trimoxazole in this setting [18].
Brucella
This common zoonotic pathogen has been successfully trea-
ted with co-trimoxazole since the 1970s. However, owing
to a lack of robust evidence, it is considered to be a sec-
ond-line treatment [19]. The data derive from many case
reports and case series dealing mainly with brucella endo-
carditis or CNS infection, usually in combination with other
drugs such as rifampicin, doxycycline and gentamicin. Sev-
eral retrospective and prospective studies have demon-
strated the efﬁcacy of co-trimoxazole in brucellosis,
including in children [20] and pregnant women [21]. Two
randomized controlled trials (RCTs) evaluated co-trimoxaz-
ole in the treatment of brucellosis. However, in one study,
co-trimoxazole was included in both treatment arms [22].
The other study compared six different treatment regimens,
including co-trimoxazole alone. All treatment arms were
comparable, except for streptomycin plus doxycycline. In
light of this information, co-trimoxazole can be considered
as a treatment option for brucellosis, especially in pregnant
women.
Burkholderia
Burkholderia cepacia . This Gram-negative pathogen causes
severe infections, especially in patients with cystic ﬁbrosis
and chronic granulomatous disease. It is highly resistant to
many antibiotics, but in vitro data show good sensitivity to
co-trimoxazole. Clinical data derive from case reports and
case series [23,24] only, and show good clinical response.
No large-scale trial was found in the literature.
Burkholderia pseudomallei . This is the causative agent of meli-
oidosis. It is a Gram-negative pathogen that is common in
Southeast Asia, causing serious infections such as pneumonia,
sepsis, intra-abdominal abscesses and skin infections, among
both locals and returning travellers. Co-trimoxazole plays an
important role in the treatment of this pathogen, although
not as monotherapy, as most of the case reports and case
series describe drug combinations, especially with ceftazi-
dime. Two RCTs compared different regimens that included
co-trimoxazole [25,26]. Another randomized trial compared
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FIG. 1. Trimethoprim–sulphamethoxazole molecular structure.
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the combination of co-trimoxazole and ceftazidime with ceft-
azidime alone, and found no signiﬁcant difference in efﬁcacy.
However, there were fewer treatment changes with co-trim-
oxazole.
Listeria monocytogenes
Since the 1980s, co-trimoxazole has been used successfully
in the treatment of L. monocytogenes, a Gram-positive bacillus
that causes serious infections such as sepsis and meningitis,
especially in older and immunosuppressed patients. Case
reports and a case series demonstrated efﬁcacy of co-trim-
oxazole in treating listeriosis, both in combination with
other drugs (such as gentamicin, amoxycillin and rifampicin)
and as monotherapy. A case–control study in solid organ
transplant patients demonstrated that co-trimoxazole pro-
phylaxis was a signiﬁcant protective factor against listeriosis
[27]. A retrospective study in patients with Listeria meningo-
encephalitis demonstrated superiority of co-trimoxazole with
ampicillin over gentamicin with ampicillin [28]. Thus, co-trim-
oxazole is a legitimate option in the treatment of Listeria
infections.
Coxiella burnetii
Very few data are available concerning the use of co-trimox-
azole in Q-fever. Case reports showed success of co-trimox-
azole alone or in combination with tetracyclines in the
treatment of Q-fever endocarditis. A retrospective analysis
of Q-fever endocarditis demonstrated good cure rates with
co-trimoxazole and tetracycline [29]. Another retrospective
study demonstrated the efﬁcacy of prolonged co-trimoxazole
therapy in pregnant women with acute Q-fever, preventing
obstetric complications, chronic Q-fever and placental infec-
tion [30]. More data are required to assess the importance
of co-trimoxazole in the treatment of Q-fever.
Tropheryma whipplei
This causative agent of Whipple’s disease has been treated
with different drug combinations, including co-trimoxazole,
especially as long-term maintenance therapy. Numerous case
reports and case series showed the efﬁcacy of co-trimoxaz-
ole in the treatment of CNS disease and classic Whipple’s
disease, either alone or in combination with ceftriaxone, or
doxycycline and others. One RCT compared meropenem
with ceftriaxone as initial treatment of Whipple’s disease.
Both groups received co-trimoxazole maintenance therapy,
with excellent results [31]. Two retrospective studies
demonstrated good results with co-trimoxazole alone or in
combination with penicillin and streptomycin [32,33]. How-
ever, one prospective study [34] and some case reports
raised the question of resistance to co-trimoxazole in
patients with relapses or failures. Bearing this in mind, co-
trimoxazole may still be considered as an important thera-
peutic option in Whipple’s disease.
Klebsiella granulomatis
Donovanosis is a sexually transmitted disease caused by
K. granulomatis, formerly known as Calymmatobacterium granu-
lomatis. Donovanosis is a rare condition limited to very few
geographical locations, such as Papua New Guinea, South
Africa, India and Brazil. Successful treatment with co-trimox-
azole was documented in the early 1980s, both in a case ser-
ies [35] and in a prospective study of 116 patients [36].
Although some recurrences and failures were documented in
these studies [37], co-trimoxazole is considered to be a sec-
ond-line choice in the European guidelines for the treatment
of donovanosis [38].
Methicillin-resistant Staphylococcus aureus (MRSA)
S. aureus, especially MRSA, is one of the most important and
problematic pathogens, both in healthcare-associated and in
community-acquired infections. The mortality rate of inpa-
tients with S. aureus infection is ﬁve times higher than in other
patients. One of the factors contributing to the high mortality
rate is the scarcity of effective and safe treatments, especially
in the case of MRSA [39]. The last decade has revealed a
growing incidence of community-acquired MRSA, affecting
healthy individuals and spreading quickly across the globe.
Co-trimoxazole has been shown to be active against
S. aureus (including MRSA) in vitro. Its components have syn-
ergistic bactericidal activity against S. aureus [40]. In our cen-
tre, the susceptibility of nosocomial bloodstream MRSA
isolates to co-trimoxazole increased from 31% in 1988 to
92% in 1997 [41]. The same trends in susceptibility to
co-trimoxazole were observed in the USA [42,43].
However, clinical evidence of co-trimoxazole efﬁcacy
against MRSA in vivo is very limited. There are a few case
reports and case series demonstrating the efﬁcacy of co-
trimoxazole in MRSA endocarditis and pulmonary infection
when used with other drugs. Surprisingly, we found seven
randomized controlled trials, seven retrospective studies and
two prospective studies evaluating co-trimoxazole in differ-
ent staphylococcal infections. One RCT demonstrated the
efﬁcacy of co-trimoxazole in preventing MRSA pneumonia in
severe burn patients [44]. Two other RCTs demonstrated
that co-trimoxazole treatment prevented recurrences after
drainage of community-acquired MRSA uncomplicated skin
abscesses in adults and children [45,46]. Other skin and soft
tissue infections and osteomyelitis caused by S. aureus were
investigated in three RCTs, which indicated equal efﬁcacy
with co-trimoxazole and other antibiotics (penicillin, cloxacil-
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lin and doxycycline) [47–49]. The only RCT comparing co-
trimoxazole with vancomycin was performed in the 1990s
on intravenous drug abusers with S. aureus bacteraemia.
Vancomycin showed superiority in methicillin-sensitive S. aur-
eus infections, but was equal to co-trimoxazole in MRSA
infections [50]. Several other small retrospective and pro-
spective studies demonstrated good clinical outcome with
co-trimoxazole in skin and soft tissue infections, infected
orthopaedic implants, osteomyelitis and otitis media. In a ret-
rospective cohort study comparing co-trimoxazole with
vancomycin in the treatment of MRSA bacteraemia, we
found similar mortality rates in both groups, and a lower
relapse rate in the co-trimoxazole group [39]. Overall, it
appears that co-trimoxazole is a promising option in treating
MRSA, although well-designed RCTs comparing it with
vancomycin are required.
Mycobacterium
In vitro susceptibility of different mycobacteria, including
Mycobacterium tuberculosis, to sulphonamides and subse-
quently to co-trimoxazole has been investigated for decades,
with varying results. However, there are several case reports
and case series showing the efﬁcacy of co-trimoxazole in
infections with Mycobacterium fortuitum, Mycobacterium mari-
num and even M. tuberculosis [51]. A retrospective study
showed a good clinical response to co-trimoxazole in
patients with M. marinum skin infections. Another retrospec-
tive study demonstrated the efﬁcacy of co-trimoxazole in the
prevention of Mycobacterium avium complex infections in
human immunodeﬁciency virus (HIV) patients. No prospec-
tive trials are available.
Protozoa
Malaria
This common parasite can cause serious infections in adults
and children. Evidence of in vitro susceptibility to co-trimox-
azole, especially for Plasmodium falciparum, has existed in
the literature for decades. In HIV patients, there is a
known relationship between prophylaxis with co-trimoxaz-
ole and a decrease in the incidence of malaria [52–54].
Eight RCTs assessed the efﬁcacy of co-trimoxazole in the
treatment of malaria, all of them in children, and most of
them in uncomplicated P. falciparum infections. Two of
these studies examined the combination of co-trimoxazole
with rifampin and isoniazid in the treatment of uncompli-
cated malaria. This combination proved to be effective and
safe as compared with chloroquine, meﬂoquine or quinine–
sulphadoxine–pyrimethamine [55,56]. Two other studies
compared co-trimoxazole–artesunate with other drug combi-
nations (chloroquine–artesunate and amodiaquine–artesunate)
in the treatment of uncomplicated P. falciparum infections, and
showed excellent results in both groups [57,58]. The remain-
ing studies demonstrated equal or superior efﬁcacy of co-trim-
oxazole alone as compared with chloroquine or
sulphadoxine–pyrimethamine in P. falciparum [59–61] and Plas-
modium vivax [62] infections. Although the data are relevant
for a speciﬁc population, co-trimoxazole is an excellent and
relatively unknown treatment option for malaria.
Acanthamoeba
This parasite can cause devastating CNS infections, with very
few effective treatment options. Case reports describing suc-
cessful treatment usually include combinations of multiple
drugs, including co-trimoxazole [63,64].
Isospora belli
Immunosuppressed individuals, speciﬁcally HIV patients, are
the target of this parasite, which causes gastrointestinal infec-
tions. Co-trimoxazole has been used as a treatment for this
pathogen since the 1980s, with several case reports and two
retrospective studies demonstrating successful treatment.
One small RCT compared co-trimoxazole with ciproﬂoxacin
in HIV patients with isosporiasis, and showed excellent
results with co-trimoxazole [65]. Another RCT demon-
strated the efﬁcacy of co-trimoxazole in the prevention of
isosporiasis after the initial episode in HIV patients [66].
These data are reﬂected in the CDC guidelines, which rec-
ommend co-trimoxazole as the treatment of choice for isos-
poriasis in HIV patients [67].
Cyclospora
Adult travellers to endemic areas are the main targets of this
pathogen, which is considered to be a cause of traveller’s
diarrhoea, as well as diarrhoea in immunocompromised
hosts. Numerous case reports and a few retrospective and
prospective studies showed success with co-trimoxazole in
diarrhoea caused by Cyclospora. Three RCTs compared co-
trimoxazole with ciproﬂoxacin or placebo for the treatment
of Cyclospora infections. Co-trimoxazole was an effective
treatment, with a low recurrence rate [65,68,69]. This infor-
mation makes co-trimoxazole a ﬁrst-line treatment for
Cyclospora infections.
Conclusions
Co-trimoxazole is a mixture of trimethoprim and sulphameth-
oxazole, which act synergistically to produce bacteriostatic
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and bactericidal effects against a wide range of Gram-positive
and Gram-negative bacteria and some protozoa. Although
most information on its efﬁcacy derive from case reports and
case series, accumulated data indicate that this old antimicro-
bial agent has great potential in treating a drug-resistant super-
bug, MRSA, as well as several other emerging pathogens.
One of the crucial questions is whether the above-men-
tioned indications will remain anecdotal or whether a real
chance exists for the strategic use of this ‘forgotten drug’.
Large-scale trials are urgently needed to explore the many
hidden potentials of this agent.
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